Merged Company Will Focus on LibiGel® in Phase III Clinical Studies for Female Sexual Dysfunction and Seek Future Opportunities for GVAX Immunotherapies
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 30, 2009 -...


June 30, 2009 | Filed Under News
Comments